Future of the EU biotechnology and biomanufacturing sector: leveraging research, boosting innovation and enhancing competitiveness

Tabled by Viktória Ferenc, Kinga Gál, Enikő Győri, András Gyürk, György Hölvényi, András László, Pál Szekeres, Annamária Vicsek, Jorge Buxadé Villalba, Hermann Tertsch, Juan Carlos Girauta Vidal, Mireia Borrás Pabón, Margarita de la Pisa Carrión, Jorge Martín Frías, Afroditi Latinopoulou, Rachel Blom, Ton Diepeveen, Marieke Ehlers, Sebastian Kruis, Sebastiaan Stöteler, Auke Zijlstra, Elisabeth Dieringer, Gerald Hauser, Petra Steger, Harald Vilimsky, Georg Mayer, Roman Haider, Filip Turek, Jaroslav Bžoch, Klara Dostalova, Ondřej Knotek, Tomáš Kubín, Jana Nagyová, Jaroslava Pokorná Jermanová, Nikola Bartůšek, Anders Vistisen, Mathilde Androuët, Jordan Bardella, Christophe Bay, Marie-Luce Brasier-Clain, Marie Dauchy, Valérie Deloge, Mélanie Disdier, Anne-Sophie Frigout, Angéline Furet, Jean-Paul Garraud, Catherine Griset, France Jamet, Virginie Joron, Fabrice Leggeri, Thierry Mariani, Aleksandar Nikolic, Philippe Olivier, Gilles Pennelle, Pascale Piera, Pierre Pimpie, Julie Rechagneux, André Rougé, Julien Sanchez, Pierre-Romain Thionnet, Rody Tolassy, Matthieu Valet, Alexandre Varaut, Séverine Werbrouck, Csaba Dömötör, Ernő Schaller-Baross, Paolo Borchia, Susanna Ceccardi, Anna Maria Cisint, Aldo Patriciello, Silvia Sardone, Raffaele Stancanelli, Isabella Tovaglieri, Roberto Vannacci

Added: 26a. Calls on the Commission to ensure that the proposal on biotechnology is in line with principles such as the respect for life and the protection of human dignity, and to guarantee that all efforts in the fields of innovation and regulatory simplification remain compatible with the highest standards of human dignity and public health; stresses that any restrictive measure adopted by a Member State on bioethical grounds – whether concerning the use of genetic engineering, synthetic biology or the manipulation of sensitive biological material – must not be regarded as an obstacle to the integration of the internal market or to industrial development, but rather as the legitimate expression of a national constitutional identity, public order and sovereign ethical choices, in accordance with Union law and the principle of subsidiarity; supports a regulatory approach based on the precautionary principle and a commitment to high ethical standards, in contrast with the product-based, innovation-driven frameworks; insists that, due to its sensitive nature, the biotechnology sector requires a principle of ethical risk assessment to ensure a balanced approach between innovation and competitiveness, freedom of research, respect for human dignity and the protection of populations;

Wording as published by the EP, in English. PE773.999v01-00